116 related articles for article (PubMed ID: 25993183)
1. Salvage therapy in patients with germ cell tumors.
Einhorn LH
Am Soc Clin Oncol Educ Book; 2015; ():e259-61. PubMed ID: 25993183
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
3. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with relapsed or primary refractory germ cell tumors.
Rejlekova K; Mego M; Sycova-Mila Z; Obertova J; Rajec J; Salek T; Mardiak J
Neoplasma; 2009; 56(3):215-23. PubMed ID: 19309224
[TBL] [Abstract][Full Text] [Related]
6. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
7. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
8. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
10. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
11. Treatment of recurrent malignant sacrococcygeal germ cell tumors: analysis of 22 patients registered in the German protocols MAKEI 83/86, 89, and 96.
Schneider DT; Wessalowski R; Calaminus G; Pape H; Bamberg M; Engert J; Waag K; Gadner H; Göbel U
J Clin Oncol; 2001 Apr; 19(7):1951-60. PubMed ID: 11283127
[TBL] [Abstract][Full Text] [Related]
12. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors.
Suleiman Y; Siddiqui BK; Brames MJ; Abonour R; Einhorn LH
Biol Blood Marrow Transplant; 2013 Jan; 19(1):161-3. PubMed ID: 22892555
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.
Urbini M; Bleve S; Schepisi G; Menna C; Gurioli G; Gianni C; De Giorgi U
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069192
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of advanced testicular cancer.
Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
[TBL] [Abstract][Full Text] [Related]
16. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced germ cell tumors.
Kondagunta GV; Motzer RJ
J Clin Oncol; 2006 Dec; 24(35):5493-502. PubMed ID: 17158534
[TBL] [Abstract][Full Text] [Related]
18. Salvage management of patients with relapsing testicular germ cell tumors.
Heidenreich A; Pfister D; Paffenholz P
Curr Opin Urol; 2021 May; 31(3):206-213. PubMed ID: 33742980
[TBL] [Abstract][Full Text] [Related]
19. Salvage Therapy for Patients With Germ Cell Tumor.
Rashdan S; Einhorn LH
J Oncol Pract; 2016 May; 12(5):437-43. PubMed ID: 27170693
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.
Koychev D; Oechsle K; Bokemeyer C; Honecker F
Int J Androl; 2011 Aug; 34(4 Pt 2):e266-73. PubMed ID: 21790652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
